Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 64-Cu-Dotatate, 64Cu-DOTA-tyr3-Octreotate, Copper Cu 64 dotatate + [4] |
Target |
Action modulators |
Mechanism SSTR modulators(Somatostatin receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 Sep 2020), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union) |
Molecular FormulaC65H87CuN14O19S2 |
InChIKeyIJRLLVFQGCCPPI-QMVMUTFZSA-K |
CAS Registry1426155-87-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuroendocrine Tumors | United States | 03 Sep 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 3 | United States | 23 Aug 2018 |
Not Applicable | - | 64Cu-DOTATATE PET/CT | mevfczqbtv(ooajwrlffi) = rqzrzlutpc ivscwlugax (arfcejdvwv ) View more | - | 01 Sep 2024 | ||
Not Applicable | - | Cu64-dotatate-PET/CT | addvpsnwyd(jkddovsptq) = zehllrkybu bykkwuehiy (nkbanvangu ) View more | - | 24 May 2024 | ||
Ga68-dotatate-PET/CT | addvpsnwyd(jkddovsptq) = ecybvxevvw bykkwuehiy (nkbanvangu ) View more | ||||||
Phase 3 | 63 | yyjbdmlbci = bmhycqtivp atedebkaxs (dcumpvzqty, anqckspzib - jvutkavpbs) View more | - | 22 Dec 2022 | |||
Phase 3 | Somatostatinoma Somatostatin Receptor-Positive | 12 | udcqxkaoqe(jdkeaisryg) = yorpmkxryl gqnqmprnzc (fiskgvziqr ) View more | Positive | 01 Jun 2020 | ||
Not Applicable | - | lhpezsscjs(fyhteqhdqi) = stvcgyhjnn ffpcdlnhlf (telydbtntp ) View more | - | 24 May 2016 | |||
lhpezsscjs(fyhteqhdqi) = magulyvllw ffpcdlnhlf (telydbtntp ) View more |